Class (w/target)	Drug sensitivity in primary GBM	ρ
Conventional chemotherapies Mitotic inhibitors		0.74 ± 0.13
Platinum based antineoplastic agents		0.79 ± 0.03
Differentiating/ epigenetic modifiers HDAC inhibitors		0.82 ± 0.12
Hormone therapies Estrogen receptor inhibitors		0.88 ± 0.10
Proteasome inhibitors		0.63 ± 0.12

Kinase inhibitors	Drug sensitivity in primary GBM	ρ
CDK inhibitors		0.82 ± 0.15
EGFR inhibitors		0.77 ± 0.20
MDM2 inhibitors		0.87 ± 0.08
MEK1/2 inhibitors		0.82 ± 0.11

Most sensitive tumor within specified category

Most resistant tumor within specified category

Additional file 4